ClinicalTrials.gg
RecruitingNCT07035314NSAIDsUpdated Jun 25, 2025

The Effect of Systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Vs Intraoperative Infiltration of Steroids in Tonsillar Bed Following Tonsillectomy on Post Tonsillectomy Pain.

An interventional study of Dexamethasone and NSAIDs in Tonsillitis Chronic, Tonsillitis Recurrent and OSA - Obstructive Sleep Apnea, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
4 Years to 10 Years
Sex
All
01

Study summary

The aim of this study is to compare the efficacy of adding paracetamol to systemic non-steroidal anti-inflammatory drugs (NSAIDs) versus adding dexamethasone as local infiltration to paracetamol on post tonsillectomy pain control.

Read the detailed description

A Prospective Randomized Controlled study. The study will be conducted at Ain Shams University hospital, Otolaryngology Department. Study period is 6 months from approval of the protocol. Study Participants will be recruited from outpatient ENT clinic, and ENT department inpatients.

02

Conditions studied

  • Tonsillitis Chronic
  • Tonsillitis Recurrent
  • OSA - Obstructive Sleep Apnea

Keywords

  • tonsillitis
  • tonsillectomy
  • post tonsillectomy pain
  • Dexamethasone infiltration in tonsillar bed
  • NSAIDs
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 75 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,950 studies on the registry; 429 are open to participants now.

Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Between 4-10 years.
  • Indications of tonsillectomy such as:

    • Recurrent acute attacks at least 7 episodes in the past year or at least 5 episodes per year for 2 years or at least 3 episodes per year for 3 years.
    • Chronic tonsillitis and hypertrophy of tonsils causing sleep apnea, difficulty in deglutition, interference in speech.
  • Tonsillectomy by cold dissection only.
  • (ASA) classification 1,2 (Normal Health, Mild systematic disease).

Exclusion criteria

Exclusion Criteria:

  • Patients with age less than 4 and more than 10 years.
  • Indications of tonsillectomy other than chronic tonsillitis such as lymphoma.
  • Patients on chronic therapy
  • level less than 10 gm/dL
  • Presence of acute infection in the upper respiratory tract, acute tonsillitis
  • (ASA) classification ASA 3,4 (Severe systematic disease such as uncontrolled Diabetes, cardiac disease, liver or kidney disease, life threating medical conditions)
  • Regular use of analgesics within a week of surgery.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and par

    1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and par

    Procedure: Dexamethasone

  • Experimental
    2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and ant

    2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol.

    Drug: NSAIDs

  • Active comparator
    3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsill

    3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsill

    Drug: Control (Standard treatment)

Interventions

  • ProcedureDexamethasone

    1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and paracetamol.

    Also known as: 1- First group: will receive local infiltration of steroids (dexamethasone) in tonsillar bed and paracetamol.

  • DrugNSAIDs

    2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol.

    Also known as: 2- Second group: will receive systemic nonsteroidal anti-inflammatory drugs in the analgesic and anti-inflammatory dosage and paracetamol.

  • DrugControl (Standard treatment)

    3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsillectomy medications in our department.

    Also known as: 3- Third group: control group will receive NSAIDs, steroids and paracetamol as standard post tonsillectomy medications in our department.

06

What researchers measure

Primary outcomes

  1. post tonsillectomy pain

    The primary endpoints that will be used is resting pain scores using virtual analogue scale; VAS score (0: no pain-10: worst pain) at DAY 0 after 6h, 24h and DAY 5 post-operatively. Where pain score will be measured at multiple points during the outcome intervals, the pain scores at the time closest to six and 24h will be used.

    Time frame: DAY 0 6h, 24h post-operatively and DAY 5 post-operatively

Secondary outcomes

  1. Additional pain medication needed

    The percentage of the patients in group 1 and 2 that will need extra analgesia

    Time frame: 2 weeks post operatively

  2. Pt feedback after tonsillectomy

    Patient satisfaction and return to normal activity.

    Time frame: 2 weeks post operatively

  3. Complications

    Adverse effects noticed such as nausea, vomiting, infection and post tonsillectomy bleeding.

    Time frame: 2 weeks post operatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Verma RR, Sriraman R, Rana SK, Ponnanna NM, Rajendar B, Ghantasala P, Rajendra L, Matur RV, Srinivasan VA. E6 protein of human papillomavirus 16 (HPV16) expressed in Escherichia coli sans a stretch of hydrophobic amino acids, enables purification of GST-DeltaE6 in the soluble form and retains the binding ability to p53. Protein Expr Purif. 2013 Nov;92(1):41-7. doi: 10.1016/j.pep.2013.08.010. Epub 2013 Sep 6. PubMed 24012792 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07035314
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Mar 8, 2025
Primary completion
Jul 1, 2025 (estimated)
Completion
Aug 1, 2025 (estimated)
Last update
Jun 25, 2025

Study contacts

Abdurrahman samir mohamed Mr, MBBS
Contact
samirabdelrahman114@gmail.com
01069466215 ext. +20

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-Inflammatory Agents, Non-Steroidal

Start the discussion